As Sanofi's Pompe disease franchise fuels its growth in rare diseases, the company has inked a $180 million settlement related to a license for a key medicine.
Viatris launches two versions of its Biocon-partnered Lantus biosimilar. Growth of AstraZeneca's star China unit dropped. The FDA has lifted a warning lettering on the Chinese drug manufacturer behind a global valsartan recall three years ago. And more.
Japan has been leveraging different policy tools to rein in drug expenditures, and that is scaring foreign pharmas away. The country is seeing “trends of a drug lag” as approvals decrease, Yasushi Okada, president of the Japan Pharmaceutical Manufacturers Association and Eisai’s chief operating officer, said.
Pfizer recently put on a drone light show in the remote mountain area of southwestern China, where people of the Yi ethnic group, also known as Nuosu, live. The campaign tried to educate local residents with some basic health tips relevant to their lifestyles while serving as a branding message to recruit talent.
Over a year into a stunning FDA warning letter, Takeda has resolved manufacturing problems at home as it gears up to make Novavax’s COVID-19 vaccine for Japan.